Skip to content

Medical emergency? What to do

Merck loses Vioxx case, told to pay $51 million

3-RXPublished August 19, 20063 min read

Key points

  • Inc. was negligent and knowingly made misrepresentations about its withdrawn pain medicine Vioxx, and awarded $51 million to the plaintiff.
  • The plaintiff, Gerald Barnett, a 62-year-old retired FBI agent who had a heart attack in 2002 after taking Vioxx for 31 months, was awarded $50 million in compensatory damages and $1 million in punitive damages.
  • Merck, which has now has lost four cases and won five in its defense of Vioxx, vowed to appeal Thursday's verdict.
  • The pain and arthritis drug had annual sales of $2.5 billion before it was recalled in 2004 after a clinical trial showed it doubled the risk of heart attack among people taking it for more than 18 months.

A federal jury on Thursday found that Merck & Co. Inc. was negligent and knowingly made misrepresentations about its withdrawn pain medicine Vioxx, and awarded $51 million to the plaintiff.

The New Orleans jury, in the second federal trial involving a Vioxx product-liability lawsuit, found that Merck had knowingly misrepresented or failed to disclose a material fact to the plaintiff's physicians and that doctors in the case and the plaintiff himself were not at fault.

The plaintiff, Gerald Barnett, a 62-year-old retired FBI agent who had a heart attack in 2002 after taking Vioxx for 31 months, was awarded $50 million in compensatory damages and $1 million in punitive damages.

Barnett, who used Vioxx for pain caused by a car accident, is a resident of South Carolina, where the suit was originally filed and which bases punitive damages on the conduct and business of the defendant solely in that state, rather than in the entire country.

Merck, which has now has lost four cases and won five in its defense of Vioxx, vowed to appeal Thursday's verdict. The company is facing at least 14,200 other lawsuits from people who claim to have been harmed by the drug.

"Both the finding and the amount of damages were totally uncalled for in this case because Merck acted appropriately in providing information to the medical, scientific and regulatory communities in a responsible and appropriate manner," Merck said in a statement.

The pain and arthritis drug had annual sales of $2.5 billion before it was recalled in 2004 after a clinical trial showed it doubled the risk of heart attack among people taking it for more than 18 months.

"This verdict will remind people that Merck still faces significant potential financial liability for Vioxx, which could wind up being at least $5 billion in the long run," said Shaojing Tong, an analyst with Mehta Partners.

Even so, Tong said he was not overly concerned with the jury award because Merck, through its appeal, will likely reduce the size of the judgment.

He noted that Merck has still won a majority of the jury verdicts, and will therefore likely stick to its strategy of fighting each case one by one, rather than attempting to conclude a costly national settlement with plaintiffs.

Money manager David Dreman, whose Merck shares form a major holding of his $17 billion portfolio, said the verdict was not all that surprising because New Orleans juries have a history of favoring plaintiffs over companies.

"This one is coming from a district that has always been anti-corporate," said Dreman, who predicted the judgment will "probably get knocked down on appeal."

Merck shares were down 1.8 percent, or 73 cents, to $40.45 in afternoon activity on the New York Stock Exchange, after touching as low as $40.30.

The stock plunged when Vioxx was recalled two years ago, but has reclaimed almost all lost ground due to earlier favorable Vioxx verdicts and enthusiasm for the company's new Gardasil cervical cancer vaccine and its experimental Januvia diabetes treatment.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug Abuse
Cancer

EU to take another look at GSK breast cancer drug

Europe's drugs regulators will take another look at GlaxoSmithKline Plc's new breast cancer pill Tyverb after new data showed a small risk of higher liver enzymes during treatment with the drug. GSK, Europe's biggest…

2 min read

Drug Abuse

Study raises caution on new painkillers

A new class of painkillers that block a receptor called TRPV1 may interfere with brain functions such as learning and memory, a new study suggests. The experiments with rat brain found that the TRPV1 receptor…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.